Logos Capital
Logos Capital is a venture capital firm that focuses on disciplined, data-driven investments in biotechnology and healthcare. Their strategy involves utilizing a proprietary data science platform, Logos Analytics, to predict clinical trial outcomes and assess the intrinsic value of opportunities to drive groundbreaking progress in healthcare.
Portfolio
17
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Stage Distribution
Portfolio
17 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Verdiva Bio | Series A | $410M | Jan 2025 |
| Gracell Biotechnologies Inc. | Growth | $150M | Aug 2023 |
| Chargel | Seed | $2.5M | Apr 2023 |
| Zeraki | Seed | $1.8M | Dec 2022 |
| ImaliPay | Seed | $3M | Apr 2022 |
| Bfree | Seed | $1.7M | Jan 2022 |
| Freenome | Series D | $300M | Dec 2021 |
| Odyssey Therapeutics, Inc. | Series A | $218M | Dec 2021 |
| Arbor Biotechnologies Inc | Series B | $215M | Nov 2021 |
| Obsidian Therapeutics | Series B | $115M | Sep 2021 |
| RareCyte | Series B | $24M | Sep 2021 |
| Interius BioTherapeutics | Series A | $76M | May 2021 |
| Gennao Bio | Series A | $40M | May 2021 |
| Shoreline Biosciences | Series A | $43M | Apr 2021 |
| DTx Pharma | Series B | $100M | Mar 2021 |
| Enliven Therapeutics | Series B | $85M | Dec 2020 |
| Athira Pharma, Inc. | Series B | $85M | Jun 2020 |
Top Co-Investors
Janus Henderson Investors7 shared
RA Capital Management6 shared
Surveyor Capital6 shared
Cormorant Asset Management5 shared
OrbiMed4 shared
Perceptive Advisors2 shared
Bain Capital Life Sciences2 shared
Section 322 shared
Woodline Partners2 shared
Deep Track Capital2 shared
Vertex Pharmaceuticals2 shared
Seedstars1 shared
Catalio Capital Management1 shared
DCVC1 shared
GV (Google Ventures)1 shared
Kaiser Permanente Ventures1 shared
Novartis Venture Fund1 shared
Polaris Venture Partners1 shared
Sands Capital1 shared
T. Rowe Price Associates, Inc.1 shared
Last updated: 3 March 2026